Cited by 240HIV-related health complications and treatmentsHIV/AIDS drug development and treatmentBone health and osteoporosis research

Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy

Bruera, Dario, Luna, Norma, David, Daniel O, Bergoglio, Liliana M, Zamudio, Javier·2003·AIDS

Abstract

OBJECTIVE: To describe the alterations in the bone metabolism of HIV-seropositive patients and evaluate the effects of antiretroviral therapies. DESIGN: Cross-sectional analytical study. METHOD AND MATERIALS: A total of 142 subjects (113 male, 29 female), aged 20-45 years were divided into four groups: group A, 33 HIV-seropositive antiretroviral-naive patients; group B1, 36 HIV-seropositive patients on antiviral therapy for over 1 year, without protease inhibitors (PI); group B2, 42 HIV-seropositive patients on combined therapy containing PI for over 1 year; and group C, 15 healthy, HIV-seronegative subjects. Bone mineral density (BMD) were determined by dual energy X-ray absorptiometry in total body, lumbar spine and proximal femur; and evaluation of serum osteocalcin, d-pyridinoline, parathyroid hormone (THP), calcium and phosphate, and urine calcium. RESULTS: BMD was significantly lower in HIV-seropositive patients in comparison with healthy controls, in all sites studied. However, no statistical differences were observed among all groups of HIV-infected patients, independently of the antiretroviral therapy. There was a significantly higher occurrence of osteopenia and osteoporosis in HIV-infected patients in comparison with controls (P < 0.0001), with no differences among treatment-naive patients and either of the treatment groups. Bone formation and resorption markers were similar among all studied groups. There was a significant correlation in all bone sites between time of infection and BMD (P < 0.02). CONCLUSIONS: BMD was significantly lower in HIV-seropositive patients in comparison with controls in lumbar spine, proximal femur and total body, without significant differences among treatment-naive patients and either of the treatment groups. Only time with HIV infection and not specific therapy was associated with BMD decreases.

Integrity signals

Registry

Crossref · 10.1097/00002030-200309050-00010

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is divergence as to whether reduced BMD in HIV patients is due to HIV retrovirus or protease inhibitor therapy.

    “HIV patients are consistently reported to display reduced BMD and increased risk of developing osteoporosis, although there is some divergence as to whether this phenomenon occurs due to the HIV retrovirus or protease inhibitor therapy (Tebas et al, 2000; Bruera et al, 2003; Amiel et al, 2004; Brown & Qaqish, 2006).”
  • HIV patients display reduced BMD and increased risk of osteoporosis.

    “HIV patients are consistently reported to display reduced BMD and increased risk of developing osteoporosis, although there is some divergence as to whether this phenomenon occurs due to the HIV retrovirus or protease inhibitor therapy (Tebas et al, 2000; Bruera et al, 2003; Amiel et al, 2004; Brown & Qaqish, 2006).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bruera, D., Luna, N., David, D. O., Bergoglio, L. M., & Zamudio, J.
Affiliations
Universidad Nacional de Córdoba (AR)
Venue
AIDS
Published
2003-09
Volume
17
Issue
13
Pages
1917-1923
ISSN
0269-9370 (ISSN-L)
OpenAlex
W2086774058
Cited by
240
References
24
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 8 · 2021: 10 · 2020: 8 · 2019: 7 · 2018: 8 · 2017: 14 · 2016: 10 · 2015: 11 · 2014: 13 · 2013: 9 · 2012: 23
FWCI
14.20
Type
journal article
Language
en
Open access
closed
Locations
  • AIDS (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords
HIV infection, bone mineral density, antiretroviral therapy, protease inhibitors, osteopenia, osteoporosis, bone metabolism, bone formation markers, bone resorption markers, osteocalcin, parathyroid hormone, duration of HIV infection
MeSH terms
Adult, Anthropometry, Bone Diseases, Metabolic, Cross-Sectional Studies, Female, Femur Neck, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Time Factors, Absorptiometry, Photon, Bone Density, HIV Infections, Anti-HIV Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review